THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 116 filers reported holding THERAVANCE BIOPHARMA INC in Q1 2023. The put-call ratio across all filers is 0.47 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $15 | 0.0% | 1,725 | 0.0% | 0.00% | – |
| Q1 2024 | $15 | -75.8% | 1,725 | -69.0% | 0.00% | – |
| Q4 2023 | $62 | +14.8% | 5,557 | -10.8% | 0.00% | – |
| Q3 2023 | $54 | -15.6% | 6,228 | 0.0% | 0.00% | -100.0% |
| Q2 2023 | $64 | -33.3% | 6,228 | -29.5% | 0.00% | 0.0% |
| Q1 2023 | $96 | -15.8% | 8,839 | -12.7% | 0.00% | 0.0% |
| Q4 2022 | $114 | -99.9% | 10,124 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $103,000 | +14.4% | 10,124 | +1.5% | 0.00% | 0.0% |
| Q2 2022 | $90,000 | -1.1% | 9,978 | +4.4% | 0.00% | 0.0% |
| Q1 2022 | $91,000 | -60.1% | 9,556 | -53.7% | 0.00% | 0.0% |
| Q4 2021 | $228,000 | +192.3% | 20,650 | +95.6% | 0.00% | 0.0% |
| Q3 2021 | $78,000 | -62.5% | 10,559 | +31.6% | 0.00% | -75.0% |
| Q4 2019 | $208,000 | -2.8% | 8,024 | +49.7% | 0.00% | -42.9% |
| Q2 2017 | $214,000 | – | 5,360 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chescapmanager LLC | 1,157,718 | $17,117,000 | 2.77% |
| Baupost Group | 8,735,168 | $129,149,000 | 1.40% |
| Orbimed Advisors | 6,219,110 | $91,950,000 | 1.16% |
| Rubric Capital Management LP | 550,747 | $8,143,000 | 0.76% |
| Cormorant Asset Management, LP | 650,072 | $9,611,000 | 0.37% |
| Rock Springs Capital Management LP | 824,018 | $12,183,000 | 0.31% |
| Virtus ETF Advisers LLC | 23,148 | $342,000 | 0.18% |
| Tekla Capital Management LLC | 298,470 | $4,413,000 | 0.16% |
| PEREGRINE CAPITAL MANAGEMENT LLC | 412,594 | $6,100,000 | 0.16% |
| NJ State Employees Deferred Compensation Plan | 38,142 | $564,000 | 0.10% |